Fundamental Analysis of AGILE THERAPEUTICS INC(NASDAQ:AGRX) stock

Fundamental Rating

Taking everything into account, AGRX scores 2 out of 10 in our fundamental rating. AGRX was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AGRX have multiple concerns. AGRX is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AGRX has reported negative net income.

In the past year AGRX has reported a negative cash flow from operations.

In the past 5 years AGRX always reported negative net income.

In the past 5 years AGRX always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of 75.60%, AGRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	75.6%
ROE	N/A
ROIC	N/A

ROA(3y)-143.37%

ROA(5y)-111.2%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 41.26%, AGRX belongs to the best of the industry, outperforming 97.00% of the companies in the same industry.

AGRX has a Gross Margin of 57.79%. This is in the better half of the industry: AGRX outperforms 66.00% of its industry peers.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	41.26%
GM	57.79%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AGRX does not have a ROIC to compare to the WACC, probably because it is not profitable.

There is no outstanding debt for AGRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -59.60, we must say that AGRX is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -59.60, AGRX is doing worse than 92.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-59.6

ROIC/WACCN/A

WACC10.87%

2.3 Liquidity

A Current Ratio of 0.58 indicates that AGRX may have some problems paying its short term obligations.

AGRX's Current ratio of 0.58 is on the low side compared to the rest of the industry. AGRX is outperformed by 93.00% of its industry peers.

A Quick Ratio of 0.44 indicates that AGRX may have some problems paying its short term obligations.

The Quick ratio of AGRX (0.44) is worse than 93.50% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.58
Quick Ratio	0.44

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 97.64% over the past year.

The Revenue has grown by 137.74% in the past year. This is a very strong growth!

EPS 1Y (TTM)97.64%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q98.98%

Revenue 1Y (TTM)137.74%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q122%

3.2 Future

AGRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.10% yearly.

Based on estimates for the next years, AGRX will show a very strong growth in Revenue. The Revenue will grow by 61.60% on average per year.

EPS Next Y93.92%

EPS Next 2Y41.61%

EPS Next 3Y26.27%

EPS Next 5Y15.1%

Revenue Next Year101%

Revenue Next 2Y92.19%

Revenue Next 3Y72.2%

Revenue Next 5Y61.6%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGRX. In the last year negative earnings were reported.

The Price/Forward Earnings ratio is 0.89, which indicates a rather cheap valuation of AGRX.

Based on the Price/Forward Earnings ratio, AGRX is valued cheaper than 100.00% of the companies in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 20.88, AGRX is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.89

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

AGRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as AGRX's earnings are expected to grow with 26.27% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.61%

EPS Next 3Y26.27%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AGRX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AGILE THERAPEUTICS INC

NASDAQ:AGRX (3/25/2024, 8:08:50 PM)

After market: 0.2408 -0.36 (-60.01%)

0.6022

+0.06 (+10.11%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.51M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.89
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	75.6%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	41.26%
GM	57.79%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.83

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.58
Quick Ratio	0.44
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)97.64%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y93.92%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)137.74%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

AGILE THERAPEUTICS INC (AGRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens